Q3 Loss of $1.79 a Share Misses Consensus as R&D Spending Climbs
LBRX has more than doubled off its 52-week low of $14.317.
Summary
LB Pharmaceuticals posted a Q3 adjusted loss of $1.79 per share, wider than the $1.62 consensus and well past the 61-cent loss a year earlier. The net loss came to $59.07 million, driven by Phase 3 R&D spending, and revenue was zero as expected for a clinical-stage biotech. Cash stood at $403.8 million at quarter-end, which management says funds operations past Q2 2029 — the balance sheet, not the P&L, is what matters here. This is the second straight quarter of a wider-than-expected loss after Q2's $1.71 versus $0.80 expected, and analysts have cut their mean estimate about 76% over three months. The stock is up 83.5% year to date and 6.4% this quarter, so the miss lands against a strong run; the $200M ATM shelf filed October 1st remains the dilution overhang to track.
At the time of this announcement, LBRX was trading at $38.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $14.32 to $50.16. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.